AMADO-KRAS-ANALYSIS

Regimen

Experimental
Panitumumab monotherapy
Control
BSC (best supportive care)

Population

Metastatic CRC, chemotherapy-refractory; landmark subgroup analysis establishing KRAS mutation as predictive biomarker for anti-EGFR non-response.

Key finding

Chemorefractory mCRC: KRAS-wt subgroup: panitumumab vs BSC mPFS 12.3 vs 7.3 wk (HR 0.45, 95% CI 0.34-0.59, p<0.0001); KRAS-mut subgroup: panitumumab vs BSC mPFS 7.4 vs 7.3 wk (HR 0.99, p=0.96) — no benefit; first randomized evidence establishing KRAS as predictive biomarker

Source: PMID 18316791

Timeline

    Guideline citations

    • NCCN Colon (p.6)
    • NCCN Rectal (p.7)